Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology Spain Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific AntibodiesRelease Date:Quality Improvement Oncology All Enhancing HCP Education in Maternal VaccinationRelease Date:Education Vaccines Saudi Arabia Diagnosis and Treatment of Cancer CachexiaRelease Date:Education Oncology All Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic DiseasesRelease Date:Education Inflammation & Immunology USA B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)Release Date:Education Oncology USA Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia AreataRelease Date:Education Inflammation & Immunology USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi ArabiaRelease Date:Research Vaccines Saudi Arabia Optimising Ulcerative Colitis Care: Bridging Knowledge Gaps, Integrating Biomarker-Based Strategies, and Advancing EquityRelease Date:Education Inflammation & Immunology Australia Surveillance of Pneumococcal Disease Serotype Distribution in Pediatric and Adult Pneumococcal Disease in TürkiyeRelease Date:Research Vaccines Turkey Surveillance of Pneumococcal Disease Serotype Distribution in Pediatric and Adult Pneumococcal Disease in TürkiyeRelease Date:Research Vaccines Turkey Title Grant Type Focus Area Country Application Due Date Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Release Date:Education Rare Disease USA Quality Improvement Grants to improve the early suspicion, identification, and the management of patients with ATTR-CMRelease Date:Quality Improvement Rare Disease Canada Develop Young Physicians to Lead the Increase in Preventive Awareness by VaccinationRelease Date:Education Vaccines Japan Optimizing maternal immunization practice and vaccination access during pregnancy in ItalyRelease Date:Quality Improvement Vaccines Italy Projects for Enhancing Regional Cancer TreatmentRelease Date:Partner: Japanese Society of Clinical OncologyQuality Improvement Oncology Japan Sickle Cell Disease (SCD) FellowshipRelease Date:Fellowship Rare Disease USA Cancer RegistryRelease Date:Research Oncology Congo, The Democratic Republic The Value of Standardized Diagnosis and Treatment in Patients with Moderate-to-Severe Atopic DermatitisRelease Date:Research Inflammation & Immunology China Real World Evidence of Abrocitinib in Adolescent Patients with Moderate-to-Severe Atopic DermatitisRelease Date:Research Inflammation & Immunology China Improving the Therapeutic Environment for Metastatic Breast CancerRelease Date:Education Oncology Japan Shared Decision-Making (SDM) in Lung CancerRelease Date:Education Oncology Japan Improving Care for Patients with Hodgkin and Non-Hodgkin’s LymphomaRelease Date:Education Oncology USA